Navigation Links
NOVAVAX Awarded Nearly $1 Million in Grants from IRS Under Qualifying Therapeutic Discovery Project
Date:11/4/2010

ROCKVILLE, Md., Nov. 4, 2010 /PRNewswire/ -- Novavax, Inc. (Nasdaq: NVAX) announced today that it has been awarded approximately $978,000 in grants under the Internal Revenue Service's Qualifying Therapeutic Discovery Project ("QTDP").  This program was created under the Patient Protection and Affordable Care Act of 2010 to provide tax credits or grants representing up to 50 percent of eligible qualified investments in therapeutic discovery projects during tax years 2009 and 2010.  

"We are gratified to receive this award in recognition of our efforts to develop novel vaccine candidates using our unique recombinant technology," said Dr. Rahul Singhvi, President and CEO of Novavax. "Novavax plans to use these funds to support advanced development of its novel virus-like-particle-based vaccine candidates, which include vaccines for seasonal and pandemic influenza, respiratory syncytial virus (RSV), and varicella-zoster virus (VZV)."  

About Novavax, Inc.

Novavax, Inc. is a clinical-stage biopharmaceutical company creating novel vaccines to address a broad range of infectious diseases worldwide, including H1N1, using advanced proprietary virus-like-particle (VLP) technology.  The company produces potent VLP-based recombinant vaccines utilizing new and efficient manufacturing approaches.  Novavax is committed to using its VLP technology to create country-specific vaccine solutions.  The company has formed a joint venture with Cadila Pharmaceuticals, named CPL Biologicals, to develop and manufacture vaccines, biological therapeutics and diagnostics in India.  Additional information about Novavax is available on the company's website: www.novavax.com.


'/>"/>
SOURCE Novavax, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1

Related biology technology :

1. Novavax Commences Clinical Testing of its Seasonal Influenza VLP Vaccine Candidate
2. Novavax Completes Enrollment of Its Seasonal Influenza VLP Vaccine Phase IIa Clinical Trial
3. Novavax CEO to Present at BIO Investor Forum 2008
4. Novavax CEO to Present at Oppenheimer 19th Annual Healthcare Conference
5. Novavax Announces Release Date of 2008 Third Quarter Financial Results and Investor Conference Call
6. Novavax CEO to Present at Lazard Capital Markets 5th Annual Healthcare Conference
7. Novavax CEO to Present at Piper Jaffray 20th Annual Healthcare Conference
8. Novavax to Present Seasonal Influenza Data Results in an Investor Conference Call on December 11, 2008
9. NOVAVAX and the University of Massachusetts Medical School Announce Preclinical Study Results for a Respiratory Syncytial Virus (RSV) Vaccine Candidate
10. Novavax CMO to Present at Phacilitate Vaccine Forum Washington 2009
11. Novavax Announces Operational Status of Its Vaccine Pilot Plant and Commercial Launch Facility
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/18/2017)... DC (PRWEB) , ... July 18, 2017 , ... ... the Allotrope Framework, and has released the first phase of the Allotrope Framework ... World’s Best Practices Awards were created to “not only elevate the critical role ...
(Date:7/17/2017)... ... July 17, 2017 , ... The Academy of Model Aeronautics (AMA) will ... Aviation Day will take place from 9 a.m. to 2 p.m. at the International ... all ages. , Aviation Adventure Day will be packed with entertaining activities for the ...
(Date:7/17/2017)... ... July 17, 2017 , ... ... a wide range of overlapping clinical features. The advancement of targeted next-generation sequencing ... of NDD research and testing. , However, designing a custom panel for ...
(Date:7/17/2017)... ... July 17, 2017 , ... DuPont Pioneer today announced ... website (openinnovation.pioneer.com) dedicated to connecting third-party innovators with DuPont Pioneer scientists is ... enabling technologies, biologicals and digital solutions. , “DuPont Pioneer is building on its ...
Breaking Biology Technology:
(Date:4/5/2017)... LONDON , April 4, 2017 KEY ... is anticipated to expand at a CAGR of 25.76% ... neurodegenerative diseases is the primary factor for the growth ... full report: https://www.reportbuyer.com/product/4807905/ MARKET INSIGHTS The ... of product, technology, application, and geography. The stem cell ...
(Date:4/3/2017)... , April 3, 2017  Data captured ... engineering platform, detected a statistically significant association ... prior to treatment and objective response of ... potential to predict whether cancer patients will ... treatment, as well as to improve both pre-infusion ...
(Date:3/30/2017)... 2017 The research team of The Hong ... fingerprint identification by adopting ground breaking 3D fingerprint minutiae recovery and ... speed and accuracy for use in identification, crime investigation, immigration control, ... ... A research team led ...
Breaking Biology News(10 mins):